For the year ending 2025-12-31, XENE had $56,451K increase in cash & cash equivalents over the period. -$279,917K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -345,910 |
| Interest receivable and accretion of discounts on marketable securities | -7,369 |
| Depreciation of property, plant and equipment | 2,543 |
| Non-cash operating lease expense | 1,313 |
| Deferred income tax recovery | -3,198 |
| Stock-based compensation | 53,707 |
| Realized loss on marketable securities | -625 |
| Unrealized foreign exchange (gain) loss | -73 |
| Unrealized fair value gain on trading securities | 0 |
| Other receivables | -104 |
| Prepaid expenses and other assets | 3,157 |
| Accounts payable and accrued liabilities | 5,511 |
| Operating lease liability | -1,297 |
| Other liabilities | 3,199 |
| Net cash used in operating activities | -279,118 |
| Purchases of property, plant and equipment | 799 |
| Purchase of marketable securities | 355,657 |
| Proceeds from marketable securities | 574,454 |
| Net cash provided by (used in) investing activities | 217,998 |
| Proceeds from offerings, net | 112,151 |
| Proceeds from exercise of stock options | 4,962 |
| Net cash provided by financing activities | 117,113 |
| Effect of exchange rate changes on cash and cash equivalents | 458 |
| Increase (decrease) in cash and cash equivalents | 56,451 |
| Cash and cash equivalents, beginning of year | 142,712 |
| Cash and cash equivalents, end of year | 199,163 |
Xenon Pharmaceuticals Inc. (XENE)
Xenon Pharmaceuticals Inc. (XENE)